Full Breakdown
Unapproved Stem-Cell Infusions for Autistic Children Expand Under Political Backing
6/12/2026, 10:09:51 PM
Core Event: Surge of Unregulated Clinics
Across Florida, Texas, California and other states, clinics are offering intravenous infusions of umbilical-cord stem cells to autistic children as young as 18 months. Treatments cost up to $20,000 per session, often require ketamine sedation, and are marketed as “regenerative medicine” promising dramatic gains in speech, socialisation and behaviour.
Background & Context: Political Patronage and Regulatory Gaps
Since assuming the health-secretary role, Robert F. Kennedy Jr. has publicly endorsed stem-cell providers, appeared at Autism Health summits, and appointed summit organiser Tracy Slepcevic to the HHS-run Autism Coordinating Committee. Simultaneously, the FDA has issued warnings that such products are “likely illegal” and have been linked to blindness, tumor formation and infections.
Key Figures & Groups
- Robert F. Kennedy Jr. – U.S. health secretary, vocal supporter.
- Mike Chan – Malaysian physician presenting a protocol using sheep and rabbit stem cells.
- Tracy Slepcevic – Autism-advocate, committee member, promoter of a 120-child trial in Tijuana.
- Ed Clay – Former MMA fighter, founder of the Cellular Performance Institute (CPI) in Tijuana, investor of $2 million in the Mexican trial.
- Greice Murphy – Founder of Better Stem (Miami), marketing “legal, compliant access” under the Right-to-Try Act.
Data & Statistics
- Duke University placebo-controlled trial: 180 autistic children, insignificant behavioural benefits.
- Upcoming Mexican trial: 120 children, funded with $2 million; CPI cites 21 PhDs and 42 MDs.
- Treatment pricing: initial consultation $300, infusion $12,500–$15,000, repeat “top-ups” encouraged.
- HHS under Kennedy: $31 million cut from autism research, thousands of senior health officials dismissed.
Official Statements & Responses
The FDA cautions that offers outside approved trials “are likely deceptive and illegal.” Kennedy has warned against a “wild-west” of alternative therapies but acknowledges that “charlatans and people who have bad results” may still emerge. Better Stem cites the 2018 Right-to-Try Act, though health-law expert Jeff Cohen notes the law applies only to terminal, life-threatening conditions.
Criticism & Opposition
Medical experts stress the absence of any credible efficacy data and highlight severe safety risks documented by the FDA. The Duke trial’s null results undermine the clinics’ claims, and the defunding of autism research is viewed as a “dangerous regulatory vacuum.”
On-the-Ground Reports
Taylor, a Utah mother, plans to spend $12,500 on an infusion for her non-speaking son Ollie, raising funds through family donations. She says the effort reflects “the weight these children carry in a world that was not designed to help them thrive.”
Conflicting Reports & Gaps
Providers assert “dramatic improvements” and “legal, compliant access,” yet the most rigorous trial shows no significant benefit, and legal analysis disputes the applicability of Right-to-Try. No independent safety data from the Mexican trial have been released.
Verbatim Quotes
- “your issue is no longer on the fringe” — Robert F. Kennedy Jr., summit address
- “Man himself is an animal, the most intelligent animal. There are hundreds of drugs from animals,” — Mike Chan, email to The Guardian
- “I would say our biggest competitor right now for CPI is the scammer and the many fly-by-night clinics operating in this space.” — Ed Clay, CPI founder
- “Technically speaking, the federal Right to Try Act covers terminal diseases and is not applicable to non life-threatening conditions even if they have no cure,” — Jeff Cohen, health-law expert
What’s Next
The Tijuana trial is slated to begin next month, with plans to seek FDA licensing for U.S. sites if early results appear promising. Regulatory scrutiny and legal challenges are expected to intensify as families continue to seek costly, unproven interventions.
